Shire Plc, which was the subject of an aborted takeover by AbbVie Inc in 2014, proved that it could do well as a stand-alone company with annual revenue rising by 22% and a more than five-fold increase in net profits, mainly as a result of product price rises, new income from an acquisition and a hefty below-the-line payment from AbbVie for failing to complete the merger.
